Realizing the Potential of the Patient Perspective

References

• Peek ME, Gorawara-Bhat R, Quinn MT, Odoms-Young A, Wilson SC, Chin MH. Patient trust in physicians and shared decision-making among African-Americans with diabetes. Health Commun. 2013;28(6):616–623. doi:10.1080/10410236.2012.710873
   PubMed Web of Science ®Google Scholar
• Beach MC, Keruly J, Moore RD. Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV? J Gen Intern Med. 2006;21(6):661–665. doi:10.1111/j.1525-1497.2006.00399.x
   PubMed Web of Science ®Google Scholar
• Harmark L, Raine J, Leufkens H, et al. Patient-reported safety information: a renaissance of pharmacovigilance? Drug Saf. 2016;39(10):883–890. doi:10.1007/s40264-016-0441-x
   PubMed Web of Science ®Google Scholar
• Beach MC, Branyon E, Saha S. Diverse patient perspectives on respect in healthcare: a qualitative study. Patient Educ Couns. 2017;100(11):2076–2080. doi:10.1016/j.pec.2017.05.010
   Web of Science ®Google Scholar
• American Medical Association. 8 reasons patients don’t take their medications; 2015. Available from: https://www.ama-assn.org/delivering-care/patient-support-advocacy/8-reasons-patients-dont-take-their-medications. Accessed September 7, 2020.
   Google Scholar
• Loyola-Sanchez A, Hazlewood G, Crowshoe L, et al. Qualitative study of treatment preferences for rheumatoid arthritis and pharmacotherapy acceptance: indigenous patient perspectives. Arthritis Care Res. 2020;72(4):544–552. doi:10.1002/acr.23869
   Web of Science ®Google Scholar
• Kretchy IA, Owusu-Daaku FT, Danquah SA, Asampong E. A psychosocial perspective of medication side effects, experiences, coping approaches and implications for adherence in hypertension management. Clin Hypertens. 2015;21(1):19. doi:10.1186/s40885-015-0028-3
   Google Scholar
• Rotenstein LS, Huckman RS, Wagle NW. Making patients and doctors happier – the potential of patient-reported outcomes. N Engl J Med. 2017;377(14):1309–1312. doi:10.1056/NEJMp1707537
   PubMed Web of Science ®Google Scholar
• Lievano F, Scarazzini L, Shen F, Duhig J, Jokinen J. The future of safety science is happening now: the modernization of the benefit-risk paradigm. Pharmacoepidemiol Drug Saf. 2017;26(8):869–874.
   Web of Science ®Google Scholar
• Doyle C, Lennox L, Bell D. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Open. 2013;3(1):e001570. doi:10.1136/bmjopen-2012-001570
   PubMed Web of Science ®Google Scholar
• Gliklich R, Dreyer N, Leavy M (eds). Registries for Evaluating Patient Outcomes: A User’s Guide. 3rd ed ed. Rockville, MD: Agency for Healthcare Research and Quality (US); 2014.
   Google Scholar
• PUBLIC LAW 114–255—DEC. 13. 21st Century Cures Act; 2016.
   Google Scholar
• PROTECT. Pharmacoepidemiological research on outcomes of therapeutics by a European Consortium; 2019. Available from: http://protectbenefitrisk.eu/index.html. Accessed January 17, 2019.
   Google Scholar
• Centre for Innovation in Regulatory Science. The CIRS-BRAT Framework; 2019. Available from: http://www.cirsci.org/brat/. Accessed March 18, 2019.
   Google Scholar
• Administration USFD. 21st Century Cures Act; 2020. Available from: https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act. Accessed September 7, 2020.
   Google Scholar
• Kluetz PG, Kanapuru B, Lemery S, et al. Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and critical path institute workshop. Value Health. 2018;21(6):742–747. doi:10.1016/j.jval.2017.09.009
   PubMed Web of Science ®Google Scholar
• Corominas H, Espadaler L, Gómez A, et al. Assessing treatment tolerability for rheumatoid arthritis. Validation and practical applications of the ‘TOL-AR-18 questionnaire’. Reumatol Clin. 2020;16(2 Pt 2):149–155. doi:10.1016/j.reuma.2018.06.005
   Web of Science ®Google Scholar
• François C, Guiraud-Diawara A, Lançon C, et al. A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting. J Mark Access Health Policy. 2017;5(1):1372026. doi:10.1080/20016689.2017.1372026
   PubMedGoogle Scholar
• Kim J, Singh H, Ayalew K, et al. Use of PRO measures to inform tolerability in oncology trials: implications for clinical review, IND safety reporting, and clinical site inspections. Clin Cancer Res. 2018;24(8):1780–1784. doi:10.1158/1078-0432.CCR-17-2555
   PubMed Web of Science ®Google Scholar
• Henon C, Lissa D, Paoletti X, et al. Patient-reported tolerability of adverse events in Phase 1 trials. ESMO Open. 2017;2(2):e000148. doi:10.1136/esmoopen-2016-000148
   Web of Science ®Google Scholar
• Thanarajasingam G, Minasian LM, Baron F, et al. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2018;5(11):e563–e598. doi:10.1016/S2352-3026(18)30051-6
   PubMed Web of Science ®Google Scholar
• Desthieux C, Hermet A, Granger B, Fautrel B, Gossec L. Patient-physician discordance in global assessment in rheumatoid arthritis: a systematic literature review with meta-analysis. Arthritis Care Res (Hoboken). 2016;68(12):1767–1773. doi:10.1002/acr.22902
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration. FDA patient-focused drug development guidance series for enhancing the incorporation of the patient’s voice in medical product development and regulatory decision making; 2019. Available from: https://www.fda.gov/drugs/developmentapprovalprocess/ucm610279.htm. Accessed March 18, 2019.
   Google Scholar
• Administration USFD. FDA and European medicines agency patient engagement cluster; 2018. Available from: https://www.fda.gov/forpatients/patientengagement/ucm507907.htm. Accessed March 19, 2019.
   Google Scholar
• Hansen MB, Nørgaard LS, Hallgreen CE. How and why to involve patients in drug development: perspectives from the pharmaceutical industry, regulatory authorities, and patient organizations. Ther Innov Regul Sci. 2019;2168479019864294.
   Web of Science ®Google Scholar
• National Institute of Health and Care Excellence. NICE provides first scientific advice on patient preference study design; 2019. Available from: https://www.benefit-risk-assessment.com/nice-provides-first-scientific-advice-on-patient-preference-study-design-14feb19/. Accessed March 18, 2019.
   Google Scholar
• Pink Sheet Pharma Intelligence. There’s more to patient experience data submissions than just guidances, advocates tell US FDA; 2018. Available from: https://pink.pharmaintelligence.informa.com/PS122745/Theres-More-To-Patient-Experience-Data-Submissions-Than-Just-Guidances-Advocates-Tell-US-FDA. Accessed March 19, 2019.
   Google Scholar
• Pink Sheet Pharma Intelligence. Patient-reported outcome data helps Dermira’s hyperhidrosis drug Qbrexza Win US FDA Nod; 2018. Available from: https://pink.pharmaintelligence.informa.com/PS123423/PatientReported-Outcome-Data-Helps-Dermiras-Hyperhidrosis-Drug-Qbrexza-Win-US-FDA-Nod. Accessed March 19, 2019.
   Google Scholar
• Pink Sheet Pharma Intelligence. Patient voice makes impact in scientific advice from EU HTA network; 2019. Available from: https://pink.pharmaintelligence.informa.com/PS141319/Patient-Voice-Makes-Impact-In-Scientific-Advice-From-EU-HTA-Network. Accessed January 14, 2020.
   Google Scholar
• Pariser DM, Hebert AA, Drew J, Quiring J, Gopalan R, Glaser DA. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: patient-reported outcomes from the ATMOS-1 and ATMOS-2 Phase III randomized controlled trials. Am J Clin Dermatol. 2019;20(1):135–145. doi:10.1007/s40257-018-0395-0
   Web of Science ®Google Scholar
• Anthony L, Ervin C, Lapuerta P, et al. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017;39(11):2158–2168. doi:10.1016/j.clinthera.2017.09.013
   PubMed Web of Science ®Google Scholar
• Kulke MH, Horsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14–23. doi:10.1200/JCO.2016.69.2780
   PubMed Web of Science ®Google Scholar
• Evans SR, Follmann D. Using outcomes to analyze patients rather than patients to analyze outcomes: a step toward pragmatism in benefit:risk evaluation. Stat Biopharm Res. 2016;8(4):386–393. doi:10.1080/19466315.2016.1207561
   PubMed Web of Science ®Google Scholar
• Pink Sheet Pharma Intelligence. Patient experience data: US FDA’s evidentiary standards should reflect intended use; 2018. Available from: https://pink.pharmaintelligence.informa.com/PS123898/Patient-Experience-Data-US-FDAs-Evidentiary-Standards-Should-Reflect-Intended-Use. Accessed March 19, 2019.
   Google Scholar
• Simon TA, Pan X, Kawabata H, Huang HY, Azoulay L. The association between bleeding and the incidence of warfarin discontinuation in patients with atrial fibrillation. Cardiovasc Ther. 2016;34(2):94–99. doi:10.1111/1755-5922.12174
   Web of Science ®Google Scholar
• Shaw Y, Bradley M, Dominique A, Michaud K, McDonald D, Simon TA. Responding resiliently to chronic disease: rheumatoid arthritis patients’ discourse on coping strategies and challenges. Ann Rheum Dis. 2018;77(Suppl 2):abstract FRI0740–HPR.
   Google Scholar
• Simon TA, Bradley M, Lovell D, et al. Using ethnography to understand transition in young adults with JIA. Pediatr Rheumatol. 2018;16(suppl 2):52.
   Google Scholar
• Havranek EP, Lapuerta P, Simon TA, L’Italien G, Block AJ, Rouleau JL. A health perception score predicts cardiac events in patients with heart failure: results from the IMPRESS trial. J Card Fail. 2001;7(2):153–157. doi:10.1054/jcaf.2001.24121
   Web of Science ®Google Scholar
• Leidy NK, Vernon M. Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics. 2008;26(5):363–370. doi:10.2165/00019053-200826050-00002
   PubMed Web of Science ®Google Scholar
• Pharmacoepidemiology Research on Outcomes of Therapeutics by a European Consortium. PhRMA BRAT (The pharmaceutical research and manufacturers of America benefit-risk action team). Available from: http://protectbenefitrisk.eu/BRAT.html. Accessed September 7, 2020.
   Google Scholar
• Gelber RD, Goldhirsch A. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol. 1986;4(12):1772–1779. doi:10.1200/JCO.1986.4.12.1772
   PubMed Web of Science ®Google Scholar
• Siebel. Risk assessments for clinical trials; 2017. Available from: https://docs.oracle.com/cd/E88140_01/books/CTMS/ctmsclinicalprog014.htm#:~:text=A%20Risk%20Assessment%20and%20Categorization%20Tool%20%28RACT%29%20template,Templates%20view%20of%20the%20Administration%20-%20Clinical%20screen. Accessed September 7, 2020.
   Google Scholar
• Belton V, Stewart T. Multiple Criteria Decision Analysis: An Integrated Approach. Norwell, MA: Kluwer Academic Publishers; 2002.
   Google Scholar
• Zidan A, Awaisu A, Hasan S, Kheir N. The Living with Medicines Questionnaire: translation and cultural adaptation into the Arabic context. Value Health Reg Issues. 2016;10:36–40. doi:10.1016/j.vhri.2016.07.001
   Google Scholar
• Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1–eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–977. doi:10.1016/j.jval.2011.06.014
   PubMed Web of Science ®Google Scholar
• Collier A, Sorensen R, Iedema R. Patients’ and families’ perspectives of patient safety at the end of life: a video-reflexive ethnography study. Int J Qual Health Care. 2016;28(1):66–73. doi:10.1093/intqhc/mzv095
   Web of Science ®Google Scholar
• Shaw Y, Metes ID, Michaud K, et al. Rheumatoid arthritis patients’ motivations for accepting or resisting disease-modifying antirheumatic drug treatment regimens. Arthritis Care Res (Hoboken). 2018;70(4):533–541. doi:10.1002/acr.23301
   Web of Science ®Google Scholar
• Smart A. A multi-dimensional model of clinical utility. Int J Qual Health Care. 2006;18(5):377–382. doi:10.1093/intqhc/mzl034
   PubMed Web of Science ®Google Scholar
• Sebastian M, Ryden A, Walding A, Papadimitrakopoulou V. Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2018;122:100–106. doi:10.1016/j.lungcan.2018.05.003
   PubMed Web of Science ®Google Scholar